• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

如何治疗与黑色素瘤分化相关基因5（MDA5）相关的快速进展性间质性肺病患者？哪些患者适合哪种免疫抑制治疗？

How to treat patients with MDA5-associated rapidly progressive interstitial lung disease? Which immunosuppressive therapy for which patients?

作者信息

Uzunhan Yurdagül, Hervier Baptiste

机构信息

Pulmonology Dept, Hôpital Avicenne, APHP, Université Sorbonne Paris Nord, INSERM U1272, Centre de Référence des Maladies Pulmonaires Rares de l'Adulte, Bobigny, France

Internal Medicine Dept, Hôpital Saint-Louis, APHP, Université Paris-Cité, INSERM U976-HIPI, Centre de Référence des Maladies Auto-Immunes Systémiques Rares d'Ile-de-France, Filière FAI2R, Paris, France.

出版信息

Eur Respir J. 2025 Jul 14;66(1). doi: 10.1183/13993003.00446-2025. Print 2025 Jul.

DOI:10.1183/13993003.00446-2025
PMID:40659468
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12256802/
Abstract

https://bit.ly/4bEfTpk

摘要

这看起来并不是一段文本内容呀，它只是一个链接：https://bit.ly/4bEfTpk ，无法按照要求进行翻译。请提供正确的文本。

相似文献

1
How to treat patients with MDA5-associated rapidly progressive interstitial lung disease? Which immunosuppressive therapy for which patients?如何治疗与黑色素瘤分化相关基因5（MDA5）相关的快速进展性间质性肺病患者？哪些患者适合哪种免疫抑制治疗？
Eur Respir J. 2025 Jul 14;66(1). doi: 10.1183/13993003.00446-2025. Print 2025 Jul.
2
Dynamics of interstitial lung disease following immunosuppressive treatment differ between antisynthetase syndrome and systemic sclerosis.免疫抑制治疗后间质性肺疾病的动态变化在抗合成酶综合征和系统性硬化症之间存在差异。
Ther Adv Respir Dis. 2025 Jan-Dec;19:17534666251336896. doi: 10.1177/17534666251336896. Epub 2025 May 8.
3
The Role of Myositis-Specific Autoantibodies and the Management of Interstitial Lung Disease in Idiopathic Inflammatory Myopathies: A Systematic Review.特发性炎性肌病中肌炎特异性自身抗体的作用及间质性肺病的治疗：系统评价。
Semin Arthritis Rheum. 2022 Dec;57:152088. doi: 10.1016/j.semarthrit.2022.152088. Epub 2022 Aug 31.
4
Management of MDA-5 antibody positive clinically amyopathic dermatomyositis associated interstitial lung disease: A systematic review.MDA-5 抗体阳性的临床无肌病性皮肌炎相关间质性肺病的治疗：系统评价。
Semin Arthritis Rheum. 2022 Apr;53:151959. doi: 10.1016/j.semarthrit.2022.151959. Epub 2022 Jan 31.
5
Two fatal cases of anti-melanoma differentiation-associated gene 5 antibody (anti-MDA5) rapidly progressive interstitial lung disease (RP-ILD): Exploring pitfalls and differences.两例抗黑色素瘤分化相关基因5抗体（抗MDA5）快速进展性间质性肺病（RP-ILD）致死病例：探究陷阱与差异
Respir Med Case Rep. 2025 Apr 18;55:102224. doi: 10.1016/j.rmcr.2025.102224. eCollection 2025.
6
Autoimmune-associated hemophagocytic syndrome complicated by anti-MDA5 antibody-positive dermatomyositis successfully treated with immunosuppressive therapy: A case report.免疫抑制治疗成功治愈自身免疫相关性噬血细胞综合征合并抗MDA5抗体阳性皮肌炎：一例报告
Medicine (Baltimore). 2025 Jul 4;104(27):e43229. doi: 10.1097/MD.0000000000043229.
7
Mortality Risk Prediction in Patients With Antimelanoma Differentiation-Associated, Gene 5 Antibody-Positive, Dermatomyositis-Associated Interstitial Lung Disease: Algorithm Development and Validation.抗黑色素瘤分化相关基因5抗体阳性、皮肌炎相关间质性肺疾病患者的死亡风险预测：算法开发与验证
J Med Internet Res. 2025 Feb 5;27:e62836. doi: 10.2196/62836.
8
Pharmacologic Treatment of Anti-MDA5 Rapidly Progressive Interstitial Lung Disease.抗MDA5快速进展性间质性肺疾病的药物治疗
Curr Treatm Opt Rheumatol. 2021;7(4):319-333. doi: 10.1007/s40674-021-00186-x. Epub 2021 Sep 28.
9
Cyclophosphamide for connective tissue disease-associated interstitial lung disease.环磷酰胺用于治疗结缔组织病相关的间质性肺疾病。
Cochrane Database Syst Rev. 2018 Jan 3;1(1):CD010908. doi: 10.1002/14651858.CD010908.pub2.
10
Exploring exhaled volatile organic compounds as potential biomarkers in anti-MDA5 antibody-positive interstitial lung disease.探索呼出的挥发性有机化合物作为抗MDA5抗体阳性间质性肺病的潜在生物标志物。
Mol Cell Biochem. 2025 Mar 18. doi: 10.1007/s11010-025-05249-4.

本文引用的文献

1
Effectiveness and safety of tofacitinib calcineurin inhibitor in interstitial lung disease secondary to anti-MDA5-positive dermatomyositis: a multicentre cohort study.托法替布联合钙调神经磷酸酶抑制剂治疗抗MDA5阳性皮肌炎继发间质性肺病的有效性和安全性：一项多中心队列研究
Eur Respir J. 2025 May 22;65(5). doi: 10.1183/13993003.01488-2024. Print 2025 May.
2
2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases.2023 年美国风湿病学会（ACR）/美国胸科学会（CHEST）系统性自身免疫性风湿病患者间质性肺病治疗指南。
Arthritis Rheumatol. 2024 Aug;76(8):1182-1200. doi: 10.1002/art.42861. Epub 2024 Jul 8.
3
Efficacy and safety of dose escalation of tofacitinib in refractory anti-MDA5 antibody-positive dermatomyositis.托法替尼递增剂量治疗难治性抗 MDA5 抗体阳性皮肌炎的疗效和安全性。
RMD Open. 2023 Jan;9(1). doi: 10.1136/rmdopen-2022-002795.
4
Predictors of rapidly progressive interstitial lung disease and mortality in patients with autoantibodies against melanoma differentiation-associated protein 5 dermatomyositis.抗黑色素瘤分化相关蛋白 5 抗体相关性皮肌炎患者快速进展性间质性肺病和死亡率的预测因素。
Rheumatology (Oxford). 2022 Nov 2;61(11):4437-4444. doi: 10.1093/rheumatology/keac094.
5
Different phenotypes in dermatomyositis associated with anti-MDA5 antibody: Study of 121 cases.抗 MDA5 抗体相关皮肌炎的不同表型：121 例研究。
Neurology. 2020 Jul 7;95(1):e70-e78. doi: 10.1212/WNL.0000000000009727. Epub 2020 Jun 2.